Clinical Trials Browser

Phase 2 × telisotuzumab vedotin × 1 year × Clear all

NCT06568939 2026-02-23

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

270 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT05513703 2025-10-24

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

9 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms